Isoeucommin A
Isoeucommin A is a lignan compound. Isoeucommin A activates the Nrf2/HO-1 pathway and induces phosphorylation of GSK-3β. Isoeucommin A reduces the levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6, decreases the oxidative stress marker MDA, increases the antioxidants SOD and GSH, and alleviates oxidative stress in mesangial cells. Isoeucommin A alleviates renal tissue injury, improves impaired renal function and enhances the viability of renal tubular epithelial cells in diabetic nephropathy models. Isoeucommin A can be used in the research of diabetic nephropathy.
For research use only. We do not sell to patients.
- CAS No.: 134859-90-8
- Formula: C27H34O12
- Molecular Weight:550.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Isoeucommin A (31.25-125 μM; 24 h) activates the Nrf2/HO-1 pathway in normal human renal mesangial cells (HRMCs)[1].
Isoeucommin A (61.3-125 μM; 24 h) activates the Nrf2/HO-1 pathway in high glucose (HG)-stimulated HRMCs by increasing p-GSK-3β levels[1].
Isoeucommin A (31.25-125 μM; 24 h) enhances the antioxidant capacity of HRMCs stimulated by high glucose (HG)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:normal human renal mesangial cells (HRMCs)
-
Concentration:31.25 μM, 61.3 μM, 125 μM
-
Incubation Time:24 h
-
Result:Significantly increased Nrf2 protein expression at 31.25 μM.
Significantly increased both Nrf2 and HO-1 protein expression at 61.3 μM and 125 μM, with the highest concentration (125 μM) producing the greatest increase in protein levels.
-
Cell Line:high-glucose (HG)-stimulated human renal mesangial cells (HRMCs)
-
Concentration:61.3 μM, 125 μM
-
Incubation Time:24 h
-
Result:Significantly increased p-GSK-3β protein expression, the p-GSK-3β/GSK-3β ratio, Nrf2 protein expression, and HO-1 protein expression compared to the HG-only group, with 125 μM producing the most robust increases.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 8 weeks old, STZ-induced diabetic nephropathy)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:i.v.; daily; 28 days
-
Result:Reduced blood glucose and increased body weight gain significantly in the high-dose group compared to the DN model group.
Reduced kidney index, serum blood urea nitrogen, serum and urine creatinine, and urinary albumin-to-creatinine ratio significantly in medium- and high-dose groups compared to the DN model group.
Reduced serum TNF-α, IL-1β, IL-6, and kidney tissue MDA levels significantly, and increased kidney tissue SOD and GSH levels significantly in all dose groups compared to the DN model group, with effects increasing in a dose-dependent manner.
Reduced inflammatory cell infiltration, glomerular enlargement, renal tubular dilation, and renal tubular epithelial cell vacuolation in a dose-dependent manner, with the high-dose group nearing normal tissue morphology.
Increased renal Nrf2 and HO-1 mRNA and protein expression in a dose-dependent manner, with statistically significant elevations compared to the DN model group.
Chemical Information
-
CAS No. 134859-90-8
-
Molecular Weight 550.55
-
Formula C27H34O12
-
SMILES
COC1=C(O)C(OC)=CC([C@@H]2[C@]3([H])[C@@](CO2)([H])[C@@H](C4=CC(OC)=C(C=C4)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)OC3)=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz